NewLimit Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 43

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $435M

  • Investors
  • 39

NewLimit General Information

Description

Developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells. The company applies single-cell genomics, machine learning and functional assays to study aging, identify epigenetic targets and develop messenger ribonucleic acid-based therapies that enhance metabolic function in liver cells, enabling researchers and medical professionals to advance treatments for age-related conditions and improve human healthspan.

Contact Information

Website
www.newlimit.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 901 Gateway Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (415)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
Corporate Office
  • 901 Gateway Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (415)

NewLimit Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NewLimit Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 02-Jun-2026 $435M Completed Generating Revenue
3. Later Stage VC (Series C) 20-Oct-2025 Completed Generating Revenue
2. Early Stage VC (Series B) 02-May-2025 $130M $202M Completed Generating Revenue
1. Early Stage VC (Series A) 07-Jan-2025 $72.2M $72.2M Completed Generating Revenue
To view NewLimit’s complete valuation and funding history, request access »

NewLimit Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C-2
Series C-1
Series C-3
Series B 7,396,950 $0.000100 $17.55 $17.55 1x $17.55 12.76%
Series A 17,218,934 $0.000100 $4.2 $4.2 1x $4.2 29.7%
To view NewLimit’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

NewLimit Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells. The
Biotechnology
South San Francisco, CA
43 As of 2025

Seattle, WA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NewLimit Competitors (71)

One of NewLimit’s 71 competitors is Oisin Biotechnologies, a Venture Capital-Backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oisin Biotechnologies Venture Capital-Backed Seattle, WA
Verge Labs Venture Capital-Backed San Francisco, CA
AltPep Venture Capital-Backed Seattle, WA
Calico Venture Capital-Backed San Francisco, CA
T3D Therapeutics Venture Capital-Backed Durham, NC
You’re viewing 5 of 71 competitors. Get the full list »

NewLimit Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

NewLimit Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026222485-A1 Compositions and methods for restoration of youthful function in cd4 naive t cells Pending 18-Apr-2025

NewLimit Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NewLimit Investors (39)

Investor Name Investor Type Holding Investor Since Participating Rounds
8VC Venture Capital Minority
Age 1 Venture Capital Minority
Black Box Ventures (New York) Venture Capital Minority
Byers Capital Investment Advisory Family Office Minority
Greenoaks Venture Capital Minority
You’re viewing 5 of 39 investors. Get the full list »

Ready to get started?

Request a free trial

NewLimit FAQs

  • When was NewLimit founded?

    NewLimit was founded in 2021.

  • Where is NewLimit headquartered?

    NewLimit is headquartered in South San Francisco, CA.

  • What is the size of NewLimit?

    NewLimit has 43 total employees.

  • What industry is NewLimit in?

    NewLimit’s primary industry is Biotechnology.

  • Is NewLimit a private or public company?

    NewLimit is a Private company.

  • What is the current valuation of NewLimit?

    The current valuation of NewLimit is .

  • What is NewLimit’s current revenue?

    The current revenue for NewLimit is .

  • How much funding has NewLimit raised over time?

    NewLimit has raised $682M.

  • Who are NewLimit’s investors?

    8VC, Age 1, Black Box Ventures (New York), Byers Capital Investment Advisory, and Greenoaks are 5 of 39 investors who have invested in NewLimit.

  • Who are NewLimit’s competitors?

    Oisin Biotechnologies, Verge Labs, AltPep, Calico, and T3D Therapeutics are some of the 71 competitors of NewLimit.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process